Aridis Pharmaceuticals, Inc. (ARDS)

OTCMKTS · Delayed Price · Currency is USD
0.0000
+0.0000 (0.00%)
At close: Sep 5, 2024
-100.00%
Market Cap 53.00
Revenue (ttm) 22.36M
Net Income (ttm) -1.14M
Shares Out 53.32M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,200
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range 0.0000 - 0.1240
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 1, 2024

About Aridis Pharmaceuticals

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 37
Stock Exchange OTCMKTS
Ticker Symbol ARDS
Full Company Profile

Financial Performance

In 2022, Aridis Pharmaceuticals's revenue was $3.09 million, an increase of 101.37% compared to the previous year's $1.54 million. Losses were -$30.37 million, -34.43% less than in 2021.

Financial Statements

News

There is no news available yet.